BIONATION 2024 Recap: Showcasing Canada’s Biotech Ecosystem 🌟 Canada’s biotech ecosystem gathered in Ottawa for BIONATION 2024 showcasing the sector's economic and social impact. Over the course of two days; BIONATION united leaders in science, innovation, and entrepreneurship with researchers, investors, policymakers, and the next generation of biotech professionals. The energy and enthusiasm across the ecosystem was undeniable, showcasing not just Canada’s potential, but its shared ambition to build world-class biotech companies on Canadian soil. The event featured insightful panels on innovation, anchor companies, investment, and talent, along with fireside chats featuring BIOTECanada’s Andrew Casey with the Minister of Health, Hon. Mark Holland, PC, MP, a keynote from astronaut Chris Hadfield, and in a pivotal announcement exclusive to BIONATION 2024, Hon. François-Philippe Champagne, Minister of Innovation, Science and Economic Development Canada | Innovation, Sciences et Développement économique Canada, announced the creation of the Health Emergency Readiness Canada agency, a crucial step in bolstering the country's pandemic preparedness and enhancing collaboration between healthcare and innovation sectors. This announcement emphasized the need for health and economic policy to work together to fully leverage Canada’s advances in science and innovation. The Takeaway: Canada has the tools, expertise, and drive to establish anchor companies and a collaborative, ambitious biotech future. Thank You to our BIOTECanada Members, industry stakeholders, and especially the BIONATION Builders for making this event a success. For a full recap of BIONATION 2024, and to view our photo gallery, visit: www.biotech.ca/BIONATION #BIONATION #BIONATION2024 #Canada #CdnPoli #innovation #biotech #biotechnology #events #health #lifesciences #investment #membership #ecosystem
BIOTECanada
Biotechnology Research
Ottawa, Ontario 12,165 followers
Solving for today. Building for tomorrow.
About us
BIOTECanada is the national industry association voice. With over 230 member companies, the Association’s membership is representative of the broader Canadian biotech ecosystem which is national in scope and comprised of pre-commercial biotech companies, global pharma and biotech companies, investors, incubator and accelerator organizations, and academia. In the context of global population growth and corresponding climate change, food sustainability, and human health needs, the biotechnology industry plays a vital role in developing solutions to help address the resulting human health and environmental challenges.
- Website
-
http://www.biotech.ca
External link for BIOTECanada
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- Ottawa, Ontario
- Type
- Nonprofit
- Founded
- 1986
Locations
-
Primary
Get directions
410 Laurier Ave W
410
Ottawa, Ontario, CA
Employees at BIOTECanada
Updates
-
Congratulations to BIOTECanada members Kapoose Creek Bio and Adapsyn Bioscience on this exciting collaboration. This exclusive licensing agreement is a promising step forward for Canada’s biotechnology ecosystem, combining world-leading AI technology with natural drug discovery to accelerate the development of vital therapies. This partnership not only strengthens Canada’s position in global biotech innovation but also brings exceptional talent and transformative tools into our national biotech landscape.
Kapoose Creek Bio is thrilled to announce that the company has entered into a global exclusive technology licensing agreement with Adapsyn Bioscience, creating a combined world-leading technology platform that harnesses AI to address the most persistent barriers in natural product drug discovery. In addition to the company’s informatics technologies, Kapoose Creek Bio is acquiring Adapsyn Bioscience’s extensive natural products collections, its chemistry laboratory housed in McMaster Innovation Park, and an outstanding team of four scientists, whose expertise spans chemistry, microbiology and computation. This strategic agreement with Adapsyn Bioscience will accelerate Kapoose Creek Bio’s drug development pipeline, which already includes two lead compounds with indications encompassing neurodegeneration and neuropsychiatric diseases, and future R&D efforts. Read our release here: https://lnkd.in/gqgHT37W #drugdiscovery #AI #biopharma #biotechpartnerships #biotechinnovation #lifesciences #biotechdeals #neurodegeneration
-
-
Congratulations to BIOTECanada Member, Integrated Nanotherapeutics Inc. on securing this coveted spot at our 2025 Investment Summit, looking forward to hearing your pitch in Whistler! The annual BIOTECanada Investment Summit (now in its 21st year) brings together an exclusive group of 100 senior-level individuals representing key sectors of the life and health sciences biotech ecosystem, including investors, commercial partners (multinational pharmaceutical companies and investment affiliates), and pre-commercial companies. The Summit provides early-stage life sciences companies with unparalleled opportunities to showcase their innovations and grow within Canada’s biotech ecosystem. It also offers participants a unique chance to connect, network, and explore investment and partnership possibilities across the industry.
Congratulations to Integrated Nanotherapeutics Inc., who was selected from this morning's pitches for a coveted spot to present at the BIOTECanada Investment Summit in Whistler, BC, in March 2025. Thank you to Ali Tehrani from the BIOTECanada Board for presenting the award to Integrated Nanotherapeutic's CEO, Chris Tam, PhD. Learn more about Invest in BC: https://lnkd.in/gcQxsdvR #LSBCinvest
-
-
Welcome to BIOTECanada's newest member, FGS Longview! FGS Longview is Canada’s leading corporate communications and public affairs firm. Longview serves a diverse range of clients across Canada and abroad from its offices in Toronto, Vancouver, Calgary, Ottawa, Winnipeg, Montréal and Victoria. Longview provides trusted advice and expert support across four practice areas: corporate and financial communications, public affairs, special situations and design & branding. Read more about FGS Longview here: https://lnkd.in/e3wBKsKq For BIOTECanada’s full membership listing, visit: https://lnkd.in/dvc8X94n #newmember #biotechnology #biotech #ecosystem #CorporateCommunications #Canada #PublicAffairs
-
-
BIOTECanada reposted this
Looking to expand your Ontario-based agri-food or agri-tech business? Bioenterprise Canada, with the support of Agriculture, Food and Agribusiness | Agriculture, Alimentation et Agroentreprise, invites Ontario organizations with agri-based products to lead Market Validation and Product Development Projects. Apply today for the opportunity to advance your research into the marketplace. Learn more and apply here: https://ow.ly/wj1850TPH4c #SustainableCdnAg #AgCanDurable
-
-
Pleased to have participated in the Canadian Association for Population Therapeutics (CAPT) conference, "Bridging the Gap to Access: Patient-Centered Care in Evolving Healthcare Systems." The event featured two highly productive days of discussions on pressing health system issues, including: ✔️ Access to drugs for rare diseases ✔️ The critical role of data in determining value, including for Outcomes- Based Agreements, and ✔️ The need to assess and enhance health system readiness for new and advanced therapies During the conference, BIOTECanada, represented by Isra Wani, and Canada's Drug Agency (CDA-AMC) presented a poster on our recent collaborative project. Together, BIOTECanada and CDA-AMC developed and tested a strategic foresight framework, offering key recommendations to guide the health system as it navigates the introduction of Advanced Therapeutic Products (ATPs). BIOTECanada members valued the opportunity to work with CDA-AMC to support system readiness for ATPs in Canada; this project represents a significant milestone in the collaboration between CDA-AMC and industry. View the scientific poster here: https://lnkd.in/eQ8dg95T
-
-
Congratulations to BIOTECanada member Alpha-9 Oncology team on their impressive $175 million Series C financing. This milestone highlights the importance of continued investment in the biotech sector, fueling the development of cutting-edge therapies and strengthening the broader ecosystem. #Biotech #Investment #Radiopharmaceuticals #Ecosystem #Innovation
Today Alpha-9 Oncology Inc. announces the closing of oversubscribed $175 million Series C financing to advance its diverse clinical pipeline of #radiopharmaceuticals for effective #cancer treatments. The Financing was led by Lightspeed Venture Partners and Ascenta Capital. Learn more: https://lnkd.in/gG3qqDgg
-
-
Congratulations to BIOTECanada member Epitopea on the successful closing of its $31 million pre-Series A financing. This significant investment highlights the importance of capital in advancing the strategic development of innovative therapies while supporting the continued growth of Canada’s biotech ecosystem. #Investment #Biotech #Innovation #Canada
A major milestone for Epitopea - we’re excited to announce the closing of our USD $31 million pre-Series A financing, bringing our total raised to over USD $45 million. This investment, supported by both new and existing investors, accelerates the development of our next-generation, tumor-selective, RNA-based immunotherapies targeting Cryptigen™ antigens. This funding will help drive Epitopea’s accelerated optimization of its off-the-shelf RNA immunotherapies and its transition to a clinical-stage company delivering differentiated immunotherapies focused on enhancing the durability of clinical response for cancer patients. 🔗 Read the Press Release: [ENG] https://lnkd.in/etU9YDA8 [FR] https://lnkd.in/e9xx6ytY Our investors: Investissement Québec, adMare BioInnovations, Jonathan Milner, Advent Life Sciences, CTI Life Sciences Fund, Cambridge Innovation Capital Fonds de solidarité FTQ, Harrington Discovery Institute at University Hospitals , IRICoR, Novateur Ventures Inc. #Biotech #Innovation #Pharma #Research #Cancer
-
Congratulations to BIOTECanada member Find Therapeutics on achieving a major milestone with the first dose administration of FTX-101, a First-in-Class remyelinating agent for chronic optic neuropathy, in Phase 1 clinical trials. After an impactful presentation at the BIOTECanada Investment Summit this past March and securing CAD 11 million in convertible debenture financing, this milestone highlights their dedication to advancing innovative therapies. It also showcases the strength of Canada’s biotech ecosystem, where strategic investments drive cutting-edge developments, boost economic growth, and reinforce Canada's position as a global leader in life sciences.
Phase 1 Clinical Study Launched! First Subject Dosed with FTX-101 Find Therapeutics is excited to announce the launch of its Phase 1 clinical study for FTX-101, a first-in-class therapeutic peptide designed to promote remyelination in the brain. This study marks the beginning of a journey toward a potential treatment for chronic optic neuropathy, a condition that severely impacts vision due to the demyelination of the optic nerve. Cleared by the FDA, this Phase 1 study is a randomized, double-blind, placebo-controlled trial evaluating the safety, tolerability, and pharmacokinetics of FTX-101 in healthy volunteers. The study includes two parts: a Single Ascending Dose (SAD) and a Multiple Ascending Dose (MAD). This study represents a major step forward in advancing research aimed at improving the lives of individuals with chronic optic neuropathy," said Philippe Douville, CEO of Find Therapeutics. "We look forward to sharing the results in 2025." Stay tuned for updates on this promising development in the fight against autoimmune demyelinating diseases. Read the full press release > https://lnkd.in/eqd469Px ––––––––––––––––––– L'étude clinique de Phase 1 est lancée ! Un premier sujet reçoit une dose de FTX-101 Find Therapeutics est heureux d'annoncer le lancement de son étude clinique de phase 1 pour FTX-101, un peptide thérapeutique de première classe conçu pour promouvoir la remyélinisation dans le cerveau. Cette étude marque le début d'un parcours vers un traitement potentiel de la neuropathie optique chronique, une maladie qui affecte gravement la vision en raison de la démyélinisation du nerf optique. Autorisée par la FDA, cette étude de phase 1, randomisée, en double aveugle et contrôlée par placebo, évalue la sécurité, la tolérabilité et le profil pharmacocinétique du FTX-101 chez des volontaires sains. Elle comporte deux phases : dose ascendante unique (SAD) et dose ascendante multiple (MAD). "Cette étude représente une étape majeure dans l'avancement de la recherche pour améliorer la vie des personnes atteintes de neuropathie optique chronique," a déclaré Philippe Douville, PDG de Find Therapeutics. "Nous sommes impatients de partager les résultats en 2025." Restez connectés pour suivre les développements prometteurs dans la lutte contre les maladies auto-immunes démyélinisantes. Lire le communiqué de presse complet > https://lnkd.in/eZAH3zbn
-
-
Congratulations to BIOTECanada member Zymeworks Inc. on dosing the first patient in their Phase 1 clinical trial of ZW171, a promising therapy for mesothelin-expressing cancers including ovarian cancer and NSCLC. This milestone underscores Zymeworks’ commitment to advancing innovative cancer treatments and highlights the critical role of Canadian biotech companies in driving global progress in life sciences. Kudos to the entire team!
We're excited to announce the initiation of our global Phase 1 trial evaluating our novel investigational therapy for mesothelin-expressing cancers including ovarian cancer and non-small cell lung cancer (NSCLC). This marks a significant milestone in our mission to bring innovative treatments to patients facing difficult-to-treat cancers and other serious diseases. Learn more about this important step in our clinical pipeline: https://lnkd.in/gT8inrJe
-